Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

Core Insights - Iovance Biotherapeutics, Inc. announced best-in-class data for its commercial TIL therapy, Amtagvi (lifileucel), showing unprecedented response rates in advanced melanoma patients [1][3] Group 1: Clinical Data - In a real-world study, 41 evaluable patients with advanced melanoma treated with Amtagvi showed a confirmed objective response rate (ORR) of 44% and a disease control rate of 73% [3] - The ORR was significantly higher at 52% for patients who had received two or fewer prior lines of therapy, compared to 33% for those with three or more lines [3] - These real-world response rates surpass the 31% ORR observed in the C-144-01 clinical trial that led to the FDA's accelerated approval of Amtagvi [3] Group 2: Expert Commentary - Dr. Lilit Karapetyan emphasized the importance of early treatment with lifileucel, noting the potential for more patients to benefit as TIL therapy adoption increases [4] - Daniel Kirby, Chief Commercial Officer of Iovance, highlighted the impressive response rates and five-year durability data, reinforcing Amtagvi's best-in-class profile [4] Group 3: Market Context - Advanced melanoma represents a significant unmet medical need, with over 8,000 annual deaths in the U.S. and more than half of first-line treatment patients progressing within 12 months [4] - The FDA granted accelerated approval for Amtagvi in February 2024 based on its ORR and duration of response from the C-144-01 trial [4] Group 4: Ongoing Research - Iovance is conducting the TILVANCE-301 Phase 3 clinical trial in frontline advanced melanoma to further confirm the clinical benefits of Amtagvi [4]